An antisense oligonucleotide therapy substantially reduced tau expression in a phase 1b trial; whether this translates to clinical improvement remains to be seen, but it could have far-reaching implications for neurodegenerative diseases more broadly.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Budd Haeberlein, S. et al. J. Prev. Alzheimers Dis. 9, 197–210 (2022).
van Dyck, C. H. et al. N. Engl. J. Med. 388, 9–21 (2023).
Mummery, C. J. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02326-3 (2023).
Wu, M. et al. Mol. Psychiatry https://doi.org/10.1038/s41380-023-02024-z (2023).
Nelson, P. T. et al. J. Neuropathol. Exp. Neurol. 71, 362–381 (2012).
Teng, E. et al. JAMA Neurol. 79, 758–767 (2022).
Roberson, E. D. et al. Science 316, 750–754 (2007).
DeVos, S. L. et al. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aag0481 (2017).
Novak, G. et al. J. Alzheimers Dis. 49, 1123–1134 (2015).
Olsson, B. et al. J. Neurol. 266, 2129–2136 (2019).
FDA. https://go.nature.com/3AwPoAt (accessed 5 April 2023).
P.A.L. receives research search support from the National Institute on Aging of the US National Institutes of Health and from the Alzheimer’s Association Part the Cloud Partnership. He is the FDA investigational new drug sponsor for a clinical trial of a drug supplied by Biohaven. He has served as a clinical site primary investigator for trials sponsored by Woolsey, Alector, Transposon and AbbVie. He also currently serves as a clinical site sub-investigator for clinical trials sponsored by Lilly, Eisai and Biogen. G.D.R. receives research support from the US National Institutes of Health, the Alzheimer’s Association, the American College of Radiology, the Rainwater Charitable Foundation and the Alliance for Therapies in Neuroscience. He has served as a paid scientific advisor to Alector, Eli Lilly, GE Healthcare, Genentech, Johnson & Johnson Merck, and Roche.
Rights and permissions
About this article
Cite this article
Ljubenkov, P.A., Rabinovici, G.D. Silencing tau to treat early Alzheimer’s disease. Nat Med (2023). https://doi.org/10.1038/s41591-023-02357-w